ReviewAdvances in therapy2019

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).

Lorena Incorvaia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.